The Female Health Company /Veru Healthcare announced the appointment of Robert H. Getzenberg, Ph.D., as Executive Vice President of Clinical Development. Dr. Getzenberg will lead the clinical development of Veru’s portfolio of drugs under development, including Tamsulosin DRS (Tamsulosin HCl extended release for oral suspension) for the treatment of benign prostatic hyperplasia (BPH), MSS-722 for male infertility, APP-944 for hot flashes in men who are on hormonal therapies for advanced prostate cancer, and APP-111 for prostate, ovarian and breast cancers. Dr. Getzenberg, most recently served as Therapeutic Area Lead, Prostate Cancer for GTx Inc.